AtaiBeckley Shares at $7.17 as Lilly Agreement Sets CVR at 42 Cents
Shares of AtaiBeckley Inc. remained flat at $7.17 as of 1 p.m. on Tuesday. This price stood 42 cents higher than Eli Lilly and Co.'s $6.75 cash offer at close.
AtaiBeckley (NASDAQ:ATAI) trades show 18% implied valuation for acquisition milestone rights
Shares of AtaiBeckley Inc. finished Monday at $7.19, standing 44 cents above the cash bid from Eli Lilly and Co.. Reporting occurred after Nasdaq’s standard session had concluded.
AtaiBeckley (NASDAQ:ATAI) shares trade with Merger CVR valued near 19% of face
AtaiBeckley, previously known as Atai Life Sciences, closed at $7.22 on Friday, trading 47 cents higher than the cash element of Eli Lilly’s offer. U.S. stock markets did not open on Sunday.
AtaiBeckley (NASDAQ:ATAI) shares reflect merger rights valued at 14% of par
AtaiBeckley Inc. was priced at $7.091 ahead of Friday’s session, declining 0.8%. The share price remained 34 cents higher than Eli Lilly and Co.’s $6.75 cash offer. Nasdaq premarket volumes were active. Trading officially opens at 9:30 a.m. EDT.
Eli Lilly (NYSE:LLY) Shares Rise After Atai Partnership Could Unlock $1 Billion in Milestones
NEW YORK, July 16, 2026, 5:08 p.m. EDT – Shares of Eli Lilly edged higher on Thursday after the drugmaker announced a deal with Atai Life Sciences, a partnership that may generate up to $1 billion in milestone payments.
AtaiBeckley (NASDAQ: ATAI) stock jumps on Lilly deal as market discounts milestones
AtaiBeckley Inc. jumped about 31% to $7.04 on Thursday. Eli Lilly and Co. agreed to buy the company for up to $3.8 billion.
AtaiBeckley Inc. (NASDAQ:ATAI) stock jumps as FDA staffing guidance spotlights BPL-003’s two-hour edge
AtaiBeckley Inc. shares climbed 15.6% to about $5.75 in Tuesday afternoon trading as investors weighed final U.S. Food and Drug Administration guidance for psychedelic-drug trials. The document expects two monitors to remain with a patient throughout a treatment session, making BPL-003’s roughly two-hour clinic model more relevant to operating costs. Duration is now a cost variable.
AtaiBeckley climbs after kicking off Phase 3 for BPL-003 in depression
AtaiBeckley Inc. jumped 7.8% to $4.14 on Tuesday. Chief Executive Srinivas Rao said the company’s lead depression drug, BPL-003, advanced into Phase 3 trials. ATAI shares on Nasdaq moved between $3.83 and $4.34. Volume was close to 10 million shares.
Psychedelic Biotech Rally: Atai Life Sciences Stock Soars 18% on FDA Breakthrough and $130M Fundraise
Atai shares exploded higher on Oct. 17, 2025. Investors bid the stock up ~17.7%, closing at roughly $6.45 ts2.tech. In after-hours trading it briefly touched ~$6.86 ts2.tech. This rally follows a week of good news: BPL-003’s FDA breakthrough, plus well-received capital raise plans. Volume on Oct. 17 was very high, reflecting heavy trading. Over 2025 the stock has skyrocketed ~348% ts2.tech, making ATAI one of the year’s top biotech performers. Its market cap now hovers around $1.2 billion ts2.tech.
ATAI Life Sciences Skyrockets on FDA Breakthrough and $130M Cash Infusion
ATAI’s stock price surged in the last few days amid a flurry of good news. Shares jumped 17.7% on Friday alone, finishing at $6.45marketbeat.com, after trading around the mid-$5 range earlier in the week. In fact, as of early Friday, ATAI was already up about 8% for the week on anticipation of the announcementsnasdaq.com. The strong finish came as investors digested multiple catalysts: a coveted FDA designation for a key drug, a fresh capital raise, and bullish commentary from analysts. Notably, after-hours trading on Friday saw ATAI climb further to $6.86, indicating continued buying momentum heading into the weekendmarketbeat.com.
TechStock² Updates
